Two investigational Ebola treatments being used in the ongoing outbreak in the Democratic Republic of the Congo are effective in laboratory studies, according to new Centers for Disease Control and Prevention research. The treatments — the antiviral remdesivir and antibodies in the ZMapp treatment — blocked growth of the virus strain causing the outbreak in human cells in the laboratory. The research suggests these treatments hold promise for allowing patients to recover from the deadly illness. The research was published yesterday in Lancet Infectious Diseases. The study also shows that the lab test most often used in the DRC and neighboring countries to diagnose Ebola — which was developed during the 2014-2016 West Africa outbreak for use against a different strain of Ebola virus — appears to be accurate for the outbreak strain now circulating in DRC.

Related News Articles

Headline
The White House May 22 released its Make America Healthy Again report that focuses on childhood chronic disease. The report highlights findings from the MAHA…
Headline
The Food and Drug Administration May 16 announced it cleared the first blood test to diagnose Alzheimer’s disease. The test, created by Fujirebio Diagnostics,…
Headline
The National Institutes of Health May 8 released an analysis that found incidences of 14 types of cancer increased among people under age 50 from 2010-2019.…
Headline
A New England Journal of Medicine study published yesterday found success in administering dostarlimab, an immunotherapy drug, to a group of 103 cancer…
Headline
Overall cancer death rates declined steadily among both men and women from 2018 through 2022, according to the National Institutes of Health's latest annual…
Headline
A study published April 14 by JAMA Network Open found that rates of pancreatic and colon cancer rose among young adults from 2000-2021. Researchers examined…